



ViroGates postpones the Annual General Meeting scheduled for 28 April 2020

8.4.2020 10:00:00 CEST | ViroGates | Notice to convene annual general meeting

Company Announcement No. 7-2020

8 April 2020

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, has decided to postpone the Company's Annual General Meeting scheduled for 28 April 2020.

The decision to postpone the Annual General Meeting is based on updated guidelines from the Danish authorities concerning the COVID-19 outbreak to ensure the safety of shareholders and employees.

ViroGates A/S has set 18 June 2020 as an indicative date for the postponed Annual General Meeting depending on the development in the COVID-19 outbreak. The Company will send invitations to shareholders a minimum of two weeks before the Annual General Meeting or issue a company announcement with a potential new date.

The revised financial calendar for 2020 has the following key dates:

25 March: Annual Report 2019

30 April: Interim Report Q1 2020

13 May*: Deadline for submission of business to be transacted at the 2020 Annual General Meeting (changed from 23 March)

18 June*: Annual General Meeting (changed from 28 April)

13 August: Interim Report Q2 2020

27 October: Interim Report Q3 2020

**To be confirmed based on the Danish authorities' guidelines concerning the COVID-19 outbreak.*

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates' suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2

diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Siemens ADVIA XPT instruments and Roche Diagnostics' cobas instruments. ViroGates works with partners to develop solutions for other platforms.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20200408-ViroGates Postpones Annual General Meeting-Company Announcement 7-2020.pdf](#)